1.10
+4.76%
Close of 9 Nov 2026, in SEK
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Iconovo
Its shares trade on Nasdaq Stockholm under the ticker ICO.ST. It has been listed since 6 April 2018. In the fiscal year to 31 December 2025, it reported revenue of SEK 1.1m and a net loss of SEK 43.4m. At that date it held total assets of SEK 131.1m and shareholders' equity of SEK 117.9m.
Iconovo AB develops, manufactures and supplies inhalation products. The company is headquartered in Lund, Skane. The company went IPO on 2018-04-06. Solutions are based on the Company’s device platforms and include formulation, analytical testing and documentation. Iconovo Ab develops products, which are a part of device family and include: ICOres, reservoir devices, ICOone, disposable unit-dose devices, ICOcap, capsule-based devices and ICOpre, pre-metered devices. Moreover, the Company offers programs, which include development of generic inhalation products, where the products are registered based on therapeutic equivalence; development of inhalation products based on a generic application programming interface (API) and new chemical entity (NCE); as well as phase I-II clinical trials using ICOone.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Health Care Equipment & Supplies
- Listed since
- 6 Apr 2018
- Employees
- 32
- Website
- iconovo.se ↗
Leadership
Pay as last reported
- Johan WäborgChief Executive Officer, since 2020
- Gunnar GårdemyrChairman, since 2021
- Mats Håkan JohanssonDirector, since 2013
- Mikael Arinder, PhDVice President-Operations, since 2016
- Anna GallonChief Financial Officer, since 2019
- Orest Lastow, PhDDirector & Chief Technology Officer, since 2013
- Roger Lassing, MBAVice President-Business Development
- Orest Lastow, PhDDirector & Chief Technology Officer, since 2013
- Ann Ulrika Gidner, MBAIndependent Director, since 2021
- Agneta Walhagen, PhDIndependent Director, since 2019
- Leif Bergvall Hansen, MBAIndependent Director, since 2018
- Maria ÃhlanderIndependent Director, since 2018
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Iconovo AB develops inhalation products including ICOres and ICOone device platforms.
- Iconovo AB offers generic inhalation product development based on therapeutic equivalence.
- Iconovo AB provides phase I-II clinical trials using ICOone device platform.
Weaknesses
- Iconovo AB has 32 full-time employees in Lund, Skane.
- Iconovo AB went public on 6 April 2018.
- Iconovo AB is a small company in the Health Care sector.
Opportunities
- Iconovo AB can expand its inhalation product portfolio with ICOcap and ICOpre devices.
- Iconovo AB can develop new chemical entity products based on API.
- Iconovo AB can offer disposable unit-dose devices as part of its solutions.
Threats
- Iconovo AB faces competition in the Health Care sector.
- Iconovo AB must comply with regulatory requirements for inhalation products.
- Iconovo AB is limited by its small size and 32 employees.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.